Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret A.s. · BIST:GENIL
Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret A.s — Gen İlaç ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş. — Q2 2025 Earnings Presentation
37 slides from Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret A.s's earnings presentation, September 2025
Slide 1: For Healthier GENerations 2025
KULA 2025 For Healthier GENerations
Slide 2: Brand
KULA Brand For Healthier GENerations
Slide 3: A View to GEN
KULA A View to 600+ 10 countries different 4 Affiliated Companies employees 22 global partner 7 Subsidiaries 7different countries 10 countries different 9 offices 13partner business abroad Turkish Medicine Industry Fastest Growing 15 Imported products Company (Since 2014) 7 different sales country 2
Slide 4: Business
KULA Business NPP Drugs Registered Imported Branded Generic Drugs which prescribed by the doctors Drugs Drugs for the treatment of diseases and In addition to original drugs, it Registered imported drugs refer to has activities on development import permission is given by the the product portfolio f
Slide 5: Strong Sales
KULA Strong Sales Q2 Sales by Years (TL / ‘000) In 2025/Q2 all-times record by quarterly sales volume TL 4,1 Bn 4.145 3.014 NPP Drug sales reached TL 1,7 Bn 1.707 Compared to the same period of 2024 1.079 761 23% growth 21/Q2 22/Q2 23/Q2 24/Q2 25/Q2 In the first half of 2025 31% growth 2024 – 2025 F
Slide 6: Drug Sales
KULA Drug 48% Activity Fields 22/Q1 22/Q2 22/Q3 22/Q4 23/Q1 23/Q2 23/Q3 23/Q4 24/Q1 24/Q2 24/Q3 24/Q4 25/Q1 25/Q2 In Production Registered Drugs sales for the first 6 months of 2025, compared to the same period of 2024 increase Exported Drugs 57 81 80 26 96 60 45 120 209 127 92 182 291 226 In Import
Slide 7: Drug Sales (Boxes)
KULA Drug Sales Total number of boxes sold in the 2nd Q2 Sales by Years (Boxes – ‘000) quarter of 2025 1.544.148 1.544 863 922 923 Compared to the same period in 2024, 742 the total number of boxes sold in the 2nd quarter of 2025 %108 increase 21/2Ç 22/2Ç 23/2Ç 24/2Ç 25/2Ç Compared to the same perio
Slide 8: Export
KULA Export* Compared to the same period of 2024 Export by Country In total Export volume in 2025/Q2 Ülke TL Azerbaijan 132.055.282 %77 increase Kazakhstan 40.719.161 Uzbekistan 8.525.451 Compared to the same period in 2024 Russia 43.108.199 Total Export in the first 6 months of 2025 Others** 1.921.
Slide 9: Profitability
KULA Profitability Profitability Consolidated Gross Profit in 2025/Q2 2025 Q2 2024 Q2 893 mn TL 893.730.934 804.072.609 Compared to the 2nd Quarter of 2024 in EBITDA Turn to Profit 350.286.167 318.637.408 Compared to the 2nd quarter of 77.753.541 2024 in Net Profit 74.145.620 Turn to Profit GROSS PR
Slide 10: Profit Margins
KULA Profit Margins Compared to the same period in 2024, Profit Margins in 2025/Q2 : PROFIT MARGINS in Net Profit Margin 2025/Q2 2024/Q2 21,47% 20,84% 1,81% Net Profit Margin 1,73% EBITDA Margin 8,17% 7,48% 1,81% 1,73% In Operating Profit Margin 0,7 base point increase GROSS PROFIT MARGIN OPERATİNG
Slide 11: Balance Sheet
KULA Balance Sheet Equities Balance Sheet TL 8,9 Bn Current Ratio Assets & Liabilities 30.06.2025 31.12.2024 1,30 Total Current Assets 8.293.699.347 6.762.131.585 Total Fixed Assets 7.963.583.519 7.601.167.171 Assets Total Assets 16.257.282.866 14.363.298.756 16+ Bn TL Total Short Term Liabilities 6
Slide 12: 2025 Expectations
KULA 2025 Expectations Sales >17.500.000.000 7.151.006.771 Price Planned Price Determination Report Planned Determination Report Gross Profit >4.200.000.000 Sales 7.151.006.771 >17,50 mr TL 1.470.704.605 Gross Profit 1.470.704.605 >4,20 mr TL Price Determination Report Planned Operating Profit Opera
Slide 13: 2025 Expectations
KULA 2025 Expectations Sales >22.750.000.000 7.151.006.771 Price Planned Price Determination Report Planned Determination Gross Profit Report >5.346.250.000 Sales 7.151.006.771 >22,75 mr TL 1.470.704.605 Gross Profit 1.470.704.605 >5,34 mr TL Price Determination Report Planned Operating Profit Opera
Slide 14: 2025 Realizations
KULA 2025 Realizations 2025 Planned Coverage Rate Sales 8.378.744.586 >22.750.000.000 36,83% Gross Profit 1.771.598.168 >5.340.000.000 33,17% Operational Profit 913.775.607 >1.930.000.000 47,34% EBITDA 557.862.785 >2.500.000.000 22,31% Gross Profit Margin 21,47% 23,50% Operating Profit Margin 10,91%
Slide 15: Income Statement
KULA Income Statement TL 30.06.2025 7.897.054.795 Net Sales 7.897.054.795 Gross Profit 1.827.890.012 Operating Profit 746.336.296 1.827.890.012 990.981.580 855.272.144 EBITDA 990.981.580 746.336.296 Net Profit 855.272.144 NET SALES GROSS PROFİT OPERATİNG EBITDA NET PROFİT PROLFİT * These are data in
Slide 16: Growing
KULA Growing An exclusive distributorship agreement was signed with UK-based Unikeris Limited for the import and supply of the drug REVCOVI® to Türkiye. For Healthier GENerations
Slide 17: Azerbaijan
KULA Azerbaijan First Local Drug Producer of Azerbaijan USD 900 mn drug market 66% GEN Shareholder USD 35 mn Investment 2 years project term 30% equity financing Incentives provided by Azerbaijan State For Healthier GENerations
Slide 18: Research and Development
KULA Research and Development TL 44 mn 34 14 R&D Investments in Continuing Number of new projects 2025/Q2 R&D Project planned for commercialization facility under construction in Azerbaijan 2 40+ Accredited Technology R&D Team R&D Center Focused Industrial Move Projects For Healthier GENerations
Slide 19: Drug Registrations
KULA Drug 201 Number of 5 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025* Toplam In the first 6 months of 2025, Registered Produced Drugs 8 1 18 2 9 17 30 24 18 16 4 147 Products In Türkiye 6 1 7 0 2 1 4 6 0 3 3 33 13 products were licensed in 2015-2025* Abroad 2 0 11 2 7 16 26 18 18 13 1 114 Tür
Slide 20: Rare Solutions For Rare Diseases
KULA Rare Solutions For Solutions for Rare Drug Research for Alzheimer and other Diseases Like SMA, MS NSCLC and other neurodegenerative cancer types illnesses With the partnerships made GEN ease access of patients Collaboration maintains with Development of a new to drugs for rare diseases the RS R
Slide 21: Strong Subsidiaries
KULA Strong GENJECT ELIXIR Sağlık Ürünleri Kimya Sanayi Ticaret A.Ş. İlaç Araştırma ve Geliştirme A.Ş. Genject, its own brand in Türkiye, manufactures single-use GEN's shareholding rate in Elixir, which is hypodermic syringes in accordance with CE standards. integrated into the GEN Production Campus
Slide 22: Innovative Investments
KULA Innovative Investments in For Healthier GENerations
Slide 23: Subsidiaries Activity and Establishment
KULA ACTIVITY AND SHARE SUBSIDIARIES ESTABLISHMENT MAIN ACTIVITY RATIO (%) PLACE USA Medical Device Development 19,30 Drug Research and Türkiye 11,70 Development Drug and Food Supplement Switzerland 4,55 Research and Development Biotechnological Medical Türkiye Device Research and 35,15 Development
Slide 24: Business Partners
KULA Business Partners For Healthier GENerations
Slide 25: Business Partners
KULA Business Partners For Healthier GENerations
Slide 26: Capacity
KULA Capacity STERILE NON-STERILE Liquid Injecton Vial Tablet and Film Coated Tablets 26.520.000 vials/year 400.000.000 tablets/year Lyophilized Injection Vial Hard Gelatin Capsule 5.300.000 vials/year 40.800.000 capsules/year Cartridges Sachet 10.200.000 cartridges/year 14.688.000 sachets/year Read
Slide 27: Solar Power Plant Investment and Sustainability
KULA USD 7 - 8 mn Solar Power Plant Investment 4,85 Mw Installed Solar Power 11,85 Mw installed capacity of the Solar Power Plant investment in Yozgat province %56 Female Manager Rate We Are Not Different, We Are Aware - Employment of Individuals with Autism %46 Female Employee Rate GEN is signatory
Slide 28: Production
KULA Production 43.000 m2 Closed Area Europe, Türkiye, Russia, Kazakhstan, Philippines, Azerbaijan GMP approved. 1.200 m2 R&D Laboratory Republic of Türkiye Minister of Science, Industry and Technology R&D Center Accreditation For Healthier GENerations
Slide 29: Stock
KULA Stock 28.06.2024 Price TL 65,29 30.06.2025 Price TL 153,00 30.06.2025 Market Size TL TL 45,90 Bn / USD 1,15 Bn GENIL BIST 100 10.647,91 ₺153,00 -%7 ₺66,29 9.948,51 28.06.2024 30.06.2025 28.06.2024 30.06.2025 For Healthier GENerations
Slide 30: Innovative Projects
KULA Innovative Project Name SUL-238 GN-037 RS-139 Indication Alzheimer's and Neurodegenerative diseases Psoriasis (Psoriasis Vulgaris) Solid Cancers Stage Phase 1 was completed Phase 2 completed. Phase 3 will be launched in 2026 Phase 1b is ongoing. The Probability of the Project Being Released, at
Slide 31: Index Inclusions
KULA NATIONAL INTERNATIONAL INDECS INDECS BIST STARS BIST ANKARA MSCI BIST PARTICIPATION 100 Small Cap BIST 500 BIST DIVIDEND BIST 100 BIST BUYBACK BIST 100-30 BIST SERVICES FTSE FTSE BIST W. AND RETAIL BIST PARTICIPATION DIVIDEND TRADE World Europe All-World BIST ALL SHARES BIST PARTICIPATION Ex-En
Slide 32: Summary
KULA Summary 30.06.2025 31.12.2024 30.06.2025 31.12.2024 ASSEST Short Term Liabilities Short Term Debts 1.140.570.895 462.633.571 Current Assets Short Term Portion of Long-Term Financial Debts 367.236.649 369.281.268 Cash and Cash Equivalents 436.063.586 633.508.925 Trade Payables Financial Assets 1
Slide 33: Equities
KULA Equities 30.06.2025 31.12.2024 EQUITIES Equity Attributable to Owners of the Parent Share Capital 300.000.000 300.000.000 Adjustment to Share Capital 1.851.732.852 1.851.732.852 Buyback Shares -36.435.654 -36.421.781 Share Premiums/Discounts 2.634.360.825 2.634.360.825 Other Comprehensive Incom
Slide 34: Summary
KULA Summary 1 Jan – 1 Jan – 1 April – 1 April – 30 June 25 30 June 24 30 June 25 30 June 24 Revenue 8.378.744.586 8.798.229.535 4.289.020.443 4.260.743.498 Cost of Sales (-) -6.607.146.418 -7.070.387.347 -3.395.289.509 -3.456.670.889 Gross Profit 1.771.598.168 1.727.842.188 893.730.934 804.072.609
Slide 35: Investor Relations
KULA Investor Relations yatirimciiliskileri@genilac.com https://www.genilac.com.tr/yatirimci-iliskileri-gen Investor Relations Specialist For Healthier GENerations
Slide 36: Disclaimer
KULA All information presented in this presentation (presentation) has been prepared by Gen İlaç ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş. (GENIL) in order to present information, projection and expressions about GENIL. The accuracy, adequacy and completeness of the information in this Presentation
Slide 37: Thank You.
KULA Thank You. For Healthier GENerations
Gen İlaç ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş. — Q2 2025 Earnings Presentation on 6ix